Using the pharmacokinetic data from LCIG phase 1 and 3 clinical studies, this analysis compared levodopa bioavailability and the intra-subject variability in levodopa plasma concentrations for the two methods of administration in the target patient population.
This study characterized the population pharmacokinetics of levodopa following jejunal administration of LCIG or oral administration of levodopa-carbidopa to subjects with advanced Parkinson’s disease.
Levodopa-carbidopa intestinal gel (LCIG) was developed to overcome the limitations of oral treatment by providing continuous delivery through intrajejunal infusion.
This contributes to the troublesome motor complications in advanced Parkinson’s disease.
Levodopa concentrations fluctuate significantly with oral treatment due to the unpredictable variability of gastric emptying and levodopa’s short half-life.
Levodopa and carbidopa combination is the primary standard treatment in Parkinson’s disease.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT Keywords Duodopa, intestinal gel, levodopa, Parkinson’s disease, population pharmacokinetics -Ĭlinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, USA and 2Department of Pharmaceutics, Faculty of Pharmacy, Cairo University, Cairo, EgyptĪccepted Article Published Online 17 January 2014 Othman, PhD, FCP, Department of Clinical Pharmacology and Pharmacometrics, AbbVie, 1 North Waukegan Road, Bldg AP13A-3, North Chicago, IL 60064, USA. Population pharmacokinetics of levodopa in subjects with advanced Parkinson’s disease: levodopa-carbidopa intestinal gel infusion vs.